Sermorelin Acetate · GHRH (1-29)
Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH (the biologically active fragment). It was the first GHRH analog developed and was previously FDA-approved as Geref for diagnostic use and pediatric growth hormone deficiency. While it has been largely superseded by Tesamorelin and CJC-1295 no DAC in modern protocols, Sermorelin remains available through compounding pharmacies and is still used in GH optimization protocols, particularly paired with GHRPs.
Bedtime dosing on empty stomach. Same fasting rules as Ipamorelin (2+ hours). Amplifies natural nighttime GH pulse.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Sermorelin binds GHRH receptors on pituitary somatotrophs, identical mechanism to Tesamorelin and CJC-1295 no DAC. It stimulates pulsatile GH release through cAMP/PKA signaling. As the native GHRH(1-29) sequence without additional modifications, it is more susceptible to DPP-IV degradation than modified analogs, resulting in a shorter effective window.
Days 1-7: Sleep improvements.
Weeks 2-6: Recovery and body composition changes beginning.
Weeks 6-16: Full body composition effects.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.
Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.
Evidence scope. Clinical review including pediatric idiopathic growth-hormone deficiency; no support for 200-300 mcg nightly adult use.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 200-300 mcg daily via SubQ injection, Daily, bedtime. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.
Primary safety claim: Injection site reaction. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
Previously FDA-approved
Geref was FDA-approved for GH deficiency diagnosis and pediatric treatment. Withdrawn for commercial reasons, not safety.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
GH pulse triggered by injection lasts longer than peptide plasma presence
Enzymatic degradation (DPP-IV and endopeptidases)
Storage. Standard BAC water 2-8C. 28 days stability.
Previously FDA-approved as Geref (withdrawn). Available through compounding. WADA prohibited under S2.
Put it to work
Open Sermorelin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Sermorelin in the app →Go deeper
The complete Sermorelin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.